IPR1 Antibody
| Code | Size | Price |
|---|
| PSI-4407-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4407-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
IPR1 Antibody: IPR1, VODI, IFI41, IFI75, Sp110 nuclear body protein, Speckled 110 kDa
Application Note:
Ipr1 antibody can be used for detection of Ipr1 by Western blot at 0.5 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
IPR1 Antibody: Susceptibility to tuberculosis (TB) in mice has recently been attributed to the IPR1 gene. IPR1 is a member of the SP100/SP140 family of nuclear body proteins and encodes a leukocyte-specific nuclear body component. The protein can function as an activator of gene transcription and may serve as a nuclear hormone receptor coactivator. Alternative splicing has been observed for this gene and three transcript variants, encoding distinct isoforms, have been identified. SP110 is the closest homolog of the IPR1 protein in humans. The IPR1/Sp110 gene product might play a role in integrating signals generated by intracellular pathogens with mechanisms controlling innate immunity, cell death, and pathogenesis. IPR1/Sp110 is up-regulated after infection with M. tuberculosis and required by Anaplasma phagocytophilum for infection of human promyelocytic cells. Defects in Sp110 are a cause of severely impaired resistance to infection by M. tuberculosis.
Background References:
- Pan H, Yan BS, Rojas M, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature2005; 434:767-72.
- Bloch DB, Nakajima A, Gulick T, et al. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol. Cell Biol.2000; 20:6138-46.
- De la Fuente J, Manzano-Roman R, Blouin EF, et al. Sp110 transcription is induced and required by Anaplasma phagocytophilum for infection of human promyelocytic cells. BMC Infect. Dis.2007; 7:110.
- Tosh K. Campbell SJ, Fielding K, et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc. Natl. Acad. Sci.2006; 103:10364-8.
Buffer:
IPR1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IPR1 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of the human IPR1.
The immunogen is located within amino acids 470 - 520 of IPR1.
The immunogen is located within amino acids 470 - 520 of IPR1.
NCBI Gene ID #:
3431
NCBI Official Name:
SP110 nuclear body protein
NCBI Official Symbol:
SP110
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_004501
Protein GI Number:
190343008
Purification:
IPR1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q9HB58
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | IPR1 Peptide | PSI-4407P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|